Hints and tips:
...Johnson & Johnson has struck a deal to buy medical device maker Shockwave Medical for $13.1bn, as the healthcare giant puts cash to work from the spin-off of its consumer health arm to pursue acquisitions...
...The planned sale would unwind the 2017 acquisition of Mead Johnson, one of its largest ever, which was made under former chief executive Rakesh Kapoor....
...“Foley insisted demand would only ever increase,” it said, causing Peloton to ramp up production before having to mothball its manufacturing when demand slowed as Covid-19 vaccines proliferated and gyms...
...The New York-based group, whose major routes include airports and the Hamptons*, has acquired exclusive rights to the scheduled passenger business of Helijet, a Canadian company flying between Vancouver,...
...Maga Inc, a pro-Trump super Pac, has booked just $6.5mn....
...Hunt gives the example of Wedgwood — owned by the Fiskars Group since 2015 — as a heritage brand pivoting to partner with leading artists under new creative director Alice Bastin....
...“We will not walk away from our employees there or hand over these manufacturing facilities to the Russian government so it can operate and benefit from them,” he said....
...& Johnson....
...Barbosa added that vaccine procurement negotiations with many pharmaceutical groups had been challenging....
...The New York-based group said it would suspend operations at Tonic Fitness Technology, the Taiwanese manufacturing facility it acquired for about $45mn less than three years ago....
...Catalent, a contract manufacturer working for the vaccine makers Moderna and Johnson & Johnson, is also prioritising large orders of jabs, meaning thousands of patients have had to do without Tepezza, a...
...These began to receive government support after a switch from investment in heavy manufacturing....
...Andrew Edgecliffe-Johnson is the FT’s US business editor. Patrick McGee is the FT’s San Francisco correspondent....
...Peloton announced sweeping cuts to its workforce and manufacturing ambitions....
...Johnson & Johnson spent $1.4bn on a contentious legal manoeuvre that created a subsidiary to manage multibillion-dollar claims relating to its talc and placed it into Chapter 11 bankruptcy, the company’s...
...Peel Ports has not pulled out of the auction, however, and the group is likely to decide on its next steps soon....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Adenovirus-based vaccines, such as Gamaleya’s Sputnik V, Oxford-AstraZeneca’s and Johnson & Johnson’s, for example, are limited by how much information they can hold and what the vaccines can be instructed...
...Boris Johnson had pledged to turn the UK into a “science superpower”. Check out today’s Big Read on how the success of mRNA vaccines is opening the way to a new generation of drugs. 4....
...Johnson & Johnson put that adage into practice over the weekend, as it took over a supplier’s factory that makes a key ingredient for its coronavirus vaccine....
...They favour themes such as renewable energy, mass consumption, manufacturing and reforms to state-owned enterprises....
...US regulators have recommended healthcare providers resume using Johnson & Johnson’s Covid-19 vaccine after concluding the benefits outweighed the risks of serious blood clotting issues....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...According to Zain Rizvi, a medicine access researcher at advocacy group Public Citizen, the “immense scarcity” of vaccines around the world is directly connected to these big pharma groups being “missing...
...Johnson & Johnson’s coronavirus vaccine has shown an overall 66 per cent efficacy rate at preventing moderate and severe Covid-19, although trial results indicate it is less effective against the virus variant...
International Edition